Ansell shares surge 6% on AGM and trading update

Ansell shares are up after management raised earnings guidance for the year.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Earnings upgrade: FY26 adjusted EPS lifted to US$1.37 to US$1.49, up from US$1.33 to US$1.45, after stronger-than-expected first-quarter trading.
  • Tariffs managed: Ansell is offsetting higher US tariffs through price increases and reduced sourcing from China, thereby protecting profits.
  • Efficiency gains: The company’s productivity program has delivered $47 million in savings, with synergies from the KBU acquisition ahead of plan.

Shares in Ansell Ltd (ASX: ANN) surged on Tuesday after the personal protective equipment manufacturer delivered a better-than-expected trading update and raised its earnings outlook at its 2025 Annual General Meeting.

At the time of writing, the Ansell share price is up 6% to $36.48, with the market reacting strongly after the company raised its guidance.

Health professional putting on gloves.

Image source: Getty Images

Trading update

Management now expects FY26 adjusted earnings per share of US$1.37 to US$1.49, up from the previously provided range of US$1.33 to US$1.45.

The upgrade follows a solid start to the financial year for Ansell, with management reporting sales and margins tracking ahead of plan, buoyed by favourable foreign-exchange trends, lower freight costs, synergy gains from its Kimberly-Clark PPE business acquisition, and ongoing manufacturing productivity improvements

Whilst US tariffs have been a hot topic this year, Ansell has found ways to manage this shift by increasing its prices and reducing its sourcing from China, which faces higher US tariffs. Management's goal is to fully offset the impact of the tariffs through a range of measures designed to protect the bottom line.

Ansell also reported solid productivity gains as its Accelerated Productivity Investment Program (APIP) continues to deliver results. The program has generated $47 million in cost savings so far in FY25, and management is targeting $50 million in cost savings for FY26. The company is also investing in a new enterprise resource planning (ERP) system to streamline operations and unlock digital efficiencies.

The integration of Kimberly-Clark's PPE business (KBU) (Ansell's largest-ever acquisition) was completed ahead of schedule, achieving $5 million in cost synergies and prompting a lift in its FY27 synergy target from $10 million to $15 million.

Ansell also reaffirmed its $200 million on-market share buyback, with $29 million completed so far this year to date.

Foolish bottom line

After a few years of losing ground following the COVID pandemic hype, Ansell is a business that is finally finding its footing. Favourable exchange rates may have contributed to this positive trading update, but this is more than just luck.

The company is creating its own luck through disciplined price increases and operational efficiency gains. With tariff risks under control, synergies running ahead of plan, and earnings guidance upgraded, Ansell's 6% share price jump is earned.

Ansell shares are now up 30% from their tariffs-related lows from earlier this year, and investor confidence is growing once again. It looks like full steam ahead for Ansell.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Still down 40%, are Pro Medicus shares primed to break out?

Two major US contract wins in as many weeks could mark a turning point in sentiment.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »